Overview
Crypto majors sit at Hyperliquid's baseline funding (+0.0013%/h ≈ +11.4% annualized) with BTC at $82,056 and ETH at $2,409.2, i.e. no crowded-long stress despite $3.28B and $2.61B of open interest. The real action is in HIP-3: a broad sweep of equity perps flipped from positive to negative funding in the latest cycle, while the index complex (SP500 +0.0002%/h, XYZ100 +0.0007%/h) is close to flat. Snapshot is 19:36 ET Monday — after the US cash close.
Highlights
- Funding flips are one-directional in equities: 12 of 13 equity flips went negative, led by xyz:RDDT −0.0050%/h (−44% ann.), xyz:GIGADEV −0.0049%, xyz:QNT −0.0040%, para:CIEN −0.0121% (−106% ann.).
- xyz:SKHX is the third-largest market at $351M OI and whipsawed from +0.0134%/h to −0.0029%/h; $387M 24h volume exceeds its OI (1.1x turnover) — fast, two-sided repositioning.
- HYPE is the OI anomaly: $1.60B OI on only $285M volume (5.6x OI/volume) — very sticky positioning versus BTC's 1.7x.
- Churn without commitment in leveraged equity exposure: xyz:SOXL turns over 3.9x its $31M OI; xyz:HYUNDAI OI fell 23.4% while price rose 242.21→243.44 (shorts covering).
- Commodities lean short: xyz:CL at $98.23 funding −0.0014%/h; para:GDX OI +28.9% on a slightly lower price.
Whales
The top-10 positions are 100% short, ~$1.18B notional. 0x5b5d5120 runs ~$592M (ETH $256M @2,322.65; BTC $212M @76,204.7; SOL $76M @94.32, 7x) and 0xb83de012 ~$474M (BTC $192M, ETH $170M, ZEC $56M, HYPE $54M). Crypto-majors shorts are underwater (−$15.1M on that BTC book) while ZEC shorts pay (+$13.6M and +$9.2M). 0xb695651d is the fragile one: BTC/ETH shorts at 20x.
Risks
- +0.0013%/h is Hyperliquid's default funding level, not conviction — reading it as bullish/bearish positioning is unsafe.
- Equity funding flips occurred after the cash close; thin after-hours liquidity can manufacture them.
- Whale data is a top-10 notional snapshot with no visibility into spot, options or cross-venue hedges — "100% short" may be basis, not directional.
Generated by Claude Opus — educational analysis, not investment advice.